Nukkleus Stock Performance
| NUKK Stock | USD 1.67 0.08 4.57% |
The company secures a Beta (Market Risk) of 4.12, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nukkleus will likely underperform. At this point, Nukkleus has a negative expected return of -0.17%. Please make sure to verify Nukkleus' semi variance, and the relationship between the treynor ratio and daily balance of power , to decide if Nukkleus performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nukkleus has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Stock's forward-looking signals remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors. ...more
Last Split Factor 1:8 | Last Split Date 2024-10-24 |
1 | Revenues Working Against Nukkleus Inc.s Share Price Following 37 percent Dive | 09/12/2024 |
2 | Nukkleus to implement 1-for-8 reverse stock split | 10/22/2024 |
3 | Nukkleus Inc. issues new shares to single investor By Investing.com - Investing.com | 11/22/2024 |
| Begin Period Cash Flow | 1.2 M |
Nukkleus |
Nukkleus Relative Risk vs. Return Landscape
If you would invest 256.00 in Nukkleus on August 27, 2024 and sell it today you would lose (89.00) from holding Nukkleus or give up 34.77% of portfolio value over 90 days. Nukkleus is currently does not generate positive expected returns and assumes 10.1446% risk (volatility on return distribution) over the 90 days horizon. In different words, 90% of stocks are less volatile than Nukkleus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nukkleus Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nukkleus' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nukkleus, and traders can use it to determine the average amount a Nukkleus' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0167
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NUKK |
Estimated Market Risk
| 10.14 actual daily | 90 90% of assets are less volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nukkleus is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nukkleus by adding Nukkleus to a well-diversified portfolio.
Nukkleus Fundamentals Growth
Nukkleus Stock prices reflect investors' perceptions of the future prospects and financial health of Nukkleus, and Nukkleus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nukkleus Stock performance.
| Return On Equity | -7.42 | ||||
| Return On Asset | -1.15 | ||||
| Profit Margin | (2.53) % | ||||
| Operating Margin | (7.94) % | ||||
| Current Valuation | 6.36 M | ||||
| Shares Outstanding | 2.53 M | ||||
| Price To Earning | (40.00) X | ||||
| Price To Book | 0.69 X | ||||
| Price To Sales | 0.41 X | ||||
| Revenue | 16.22 M | ||||
| Gross Profit | (661.4 K) | ||||
| EBITDA | (1.49 M) | ||||
| Net Income | (11.85 M) | ||||
| Cash And Equivalents | 23.14 K | ||||
| Total Debt | 3.65 M | ||||
| Current Ratio | 0.22 X | ||||
| Book Value Per Share | (6.61) X | ||||
| Cash Flow From Operations | 1.62 M | ||||
| Earnings Per Share | (19.36) X | ||||
| Market Capitalization | 4.43 M | ||||
| Total Asset | 18.36 M | ||||
| Retained Earnings | (14.34 M) | ||||
| Working Capital | 895 K | ||||
| Current Asset | 3.46 M | ||||
| Current Liabilities | 2.56 M | ||||
About Nukkleus Performance
By examining Nukkleus' fundamental ratios, stakeholders can obtain critical insights into Nukkleus' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Nukkleus is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.41) | (1.48) | |
| Days Of Inventory On Hand | (57.25) | (60.12) | |
| Return On Capital Employed | (1.18) | (1.12) | |
| Return On Assets | (0.79) | (0.83) | |
| Return On Equity | (1.71) | (1.62) |
Things to note about Nukkleus performance evaluation
Checking the ongoing alerts about Nukkleus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nukkleus help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nukkleus generated a negative expected return over the last 90 days | |
| Nukkleus has high historical volatility and very poor performance | |
| Nukkleus may become a speculative penny stock | |
| Nukkleus was previously known as Brilliant Acquisition Corp and was traded on NASDAQ Exchange under the symbol BRLI. | |
| Nukkleus currently holds 3.65 M in liabilities. Nukkleus has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Nukkleus' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 16.22 M. Net Loss for the year was (11.85 M) with loss before overhead, payroll, taxes, and interest of (661.4 K). | |
| Nukkleus has a poor financial position based on the latest SEC disclosures | |
| About 35.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Nukkleus Inc. issues new shares to single investor By Investing.com - Investing.com |
- Analyzing Nukkleus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nukkleus' stock is overvalued or undervalued compared to its peers.
- Examining Nukkleus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nukkleus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nukkleus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nukkleus' stock. These opinions can provide insight into Nukkleus' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nukkleus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For more information on how to buy Nukkleus Stock please use our How to buy in Nukkleus Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nukkleus. If investors know Nukkleus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nukkleus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.36) | Revenue Per Share 7.024 | Quarterly Revenue Growth (0.97) | Return On Assets (1.15) | Return On Equity (7.42) |
The market value of Nukkleus is measured differently than its book value, which is the value of Nukkleus that is recorded on the company's balance sheet. Investors also form their own opinion of Nukkleus' value that differs from its market value or its book value, called intrinsic value, which is Nukkleus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nukkleus' market value can be influenced by many factors that don't directly affect Nukkleus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nukkleus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nukkleus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nukkleus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.